Yazar "Özdoğan, Mustafa" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim
    Öğe
    Correlation of Serum Leptin Level and Waist-to-hip Ratio (WHR) With Overall Survival of Patients With Metastatic Breast Cancer (MBC) Treated With Aromatase Inhibitors (AIs).
    (Amer Soc Clinical Oncology, 2013) Artac, Mehmet; Bozcuk, Hakan; Kıyıcı, Aysel; Eren, Orhan Önder; Boruban, Melih Cem; Özdoğan, Mustafa
    Introduction Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Methods Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Results Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was C19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91). Conclusions This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.
  • Küçük Resim Yok
    Öğe
    THE IMPACT OF LEPTIN AND ESTRADIOL LEVELS ON CLINICAL OUTCOMES IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH AROMATASE INHIBITORS (AIS)
    (OXFORD UNIV PRESS, 2008) Artaç, Mehmet; Samur, Mustafa; Kıyıcı, Aysel; Afacan, Berna; Özdoğan, Mustafa; Bozcuk, Hakan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The impact of waist-to-hip ratio (WHR) on survival in metastatic breast cancer patients treated with aromatase inhibitors (AIs)
    (AMER SOC CLINICAL ONCOLOGY, 2007) Artaç, Mehmet; Samur, Mustafa; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors
    (Churchill Livingstone, 2008) Artaç, Mehmet; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa; Samur, Mustafa
    We aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age, c-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of <0.92 and ?0.92 (Log rank statistic = 9.76, P = 0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of <0.92 and ?0.92 were 423 versus 1004 days (Log rank statistic = 6.37, P = 0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs. © 2008 Elsevier Ltd. All rights reserved.
  • Küçük Resim Yok
    Öğe
    The predictors of information needs and different views of patients and relatives on disclosure and treatment participation: A multicentric survey study
    (AMER SOC CLINICAL ONCOLOGY, 2009) Özdoğan, Mustafa; Bozcuk, Hakan; Er, O.; Abalı, Hüseyin; Coşkun, Hasan Şenol; Zengin, N; Artaç, Mehmet; Savaş, Burhan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
    (SPRINGER, 2010) Artaç, Mehmet; Bozcuk, Hakan; Pehlivan, Sacide; Akcan, Songül; Pehlivan, Mustafa; Sever, Tuğçe; Özdoğan, Mustafa
    Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.